Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial - Weber, J; Del Vecchio, M; Mandala, M; Gogas, H; Arance, A; Dalle, S; Cowey, C; Schenker, M; Grob, J; Chiarion-Sileni, V; Marquez-Rodas, I; Butler, M; et al. (Oxford University Press, 2019)